Melphalan

Generic Name
Melphalan
Brand Names
Alkeran, Evomela, Phelinun, Pepaxti
Drug Type
Small Molecule
Chemical Formula
C13H18Cl2N2O2
CAS Number
148-82-3
Unique Ingredient Identifier
Q41OR9510P
Background

Melphalan is a nitrogen mustard or bischloroethylamine type alkylating agent. It was first synthesized in the early 1950s by substituting L-phenylalanine for the methyl group on nitrogen mustard. Melphalan is used in the treatment of multiple myeloma and ovarian carcinoma. It is also used for high-conditioning before hematopoietic stem cell transplant. It is also used to treat uveal melanoma with unresectable hepatic metastases.

Indication

Melphalan is indicated for use as a high-dose conditioning treatment prior to hematopoietic stem cell transplantation in patients with multiple myeloma. It is also indicated for the palliative treatment of multiple myeloma and for the palliation of non-resectable epithelial carcinoma of the ovary.

Melphalan is a component of HEPZATO KIT, a liver-directed therapy indicated for the treatment of adults with uveal melanoma with unresectable hepatic metastases affecting less than 50% of the liver and no extrahepatic disease or extrahepatic disease limited to the bone, lymph nodes, subcutaneous tissues, or lung that is amenable to resection or radiation.

Associated Conditions
Multiple Myeloma (MM), Unresectable Liver Metastasis, Unresectable Ovarian Cancer (Epithelial)
Associated Therapies
Conditioning regimens for allogeneic stem cell transplantation therapy
Clinical Trials
Related News

Umbilical Cord Blood (UCB) Transplant, Fludarabine, Melphalan, and Anti-thymocyte Globulin (ATG) in Treating Patients With Hematologic Cancer

First Posted Date
2009-01-22
Last Posted Date
2012-03-23
Lead Sponsor
Northside Hospital, Inc.
Target Recruit Count
5
Registration Number
NCT00827099
Locations
🇺🇸

Blood and Marrow Transplant Group of Georgia, Atlanta, Georgia, United States

Haploidentical Hematopoietic Stem Cell Transplantation Using A Novel Clofarabine Containing Conditioning Regimen For Patients With Refractory Hematologic Malignancies

First Posted Date
2009-01-16
Last Posted Date
2017-01-02
Lead Sponsor
St. Jude Children's Research Hospital
Target Recruit Count
34
Registration Number
NCT00824135
Locations
🇺🇸

St. Jude Children's Research Hospital, Memphis, Tennessee, United States

Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders

First Posted Date
2008-12-04
Last Posted Date
2019-03-27
Lead Sponsor
Columbia University
Target Recruit Count
1
Registration Number
NCT00801931
Locations
🇺🇸

Columbia Presbyterian Medical Center, New York, New York, United States

Total Marrow and Total Lymph Node Irradiation, Fludarabine, and Melphalan Followed By Donor Stem Cell Transplant in Treating Patients With Advanced Hematological Cancer That Has Not Responded to Treatment

First Posted Date
2008-12-01
Last Posted Date
2015-06-08
Lead Sponsor
City of Hope Medical Center
Target Recruit Count
6
Registration Number
NCT00800150
Locations
🇺🇸

City of Hope Comprehensive Cancer Center, Duarte, California, United States

A Study to Further Assess Safety and Effectiveness Data of the Bortezomib(Velcade)/Melphalan/Prednisone (BMP) Regimen in Previously Untreated and Transplant Ineligible Multiple Myeloma Patients

First Posted Date
2008-12-01
Last Posted Date
2015-12-02
Lead Sponsor
Janssen-Ortho Inc., Canada
Registration Number
NCT00799539

Combination High Dose Melphalan and Autologous Peripheral Blood Stem Cell (PBSC) Transplant With Bortezomib for Multiple Myeloma: A Dose and Schedule Finding Study

First Posted Date
2008-11-19
Last Posted Date
2012-08-30
Lead Sponsor
Emory University
Target Recruit Count
39
Registration Number
NCT00793650
Locations
🇺🇸

Emory University Winship Cancer Institute, Atlanta, Georgia, United States

Autologous or Syngeneic Stem Cell Transplant Followed by Donor Stem Cell Transplant and Bortezomib in Treating Patients With Newly Diagnosed High-Risk, Relapsed, or Refractory Multiple Myeloma

First Posted Date
2008-11-19
Last Posted Date
2020-01-22
Lead Sponsor
Fred Hutchinson Cancer Center
Target Recruit Count
32
Registration Number
NCT00793572
Locations
🇺🇸

Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States

Tandem High-dose Chemotherapy and Autologous Stem Cell Rescue in Patients With High-risk Neuroblastoma

First Posted Date
2008-11-19
Last Posted Date
2018-09-18
Lead Sponsor
Samsung Medical Center
Target Recruit Count
40
Registration Number
NCT00793845
Locations
🇰🇷

Samsung Medical Center, Seoul, Korea, Republic of

Bortezomib, Thalidomide, and Dexamethasone After Melphalan and Stem Cell Transplant in Treating Patients With Stage I-III Multiple Myeloma

First Posted Date
2008-11-17
Last Posted Date
2021-08-19
Lead Sponsor
City of Hope Medical Center
Target Recruit Count
45
Registration Number
NCT00792142
Locations
🇺🇸

City of Hope Medical Center, Duarte, California, United States

Melphalan, Bortezomib, and Stem Cell Transplant in Treating Patients With Primary Systemic Amyloidosis

First Posted Date
2008-11-13
Last Posted Date
2017-02-06
Lead Sponsor
Boston Medical Center
Target Recruit Count
10
Registration Number
NCT00790647
Locations
🇺🇸

Boston University Cancer Research Center, Boston, Massachusetts, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy